Kinpeygo (budesonide) is a corticosteroid‐based therapy approved for the treatment of adults with rapidly progressing primary immunoglobulin A nephropathy. This article discusses its mode of action, efficacy and adverse effects.
No takes yet. Share an insight, caveat, or question.
A 2024 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: